Advaxis Inc (NASDAQ:ADXS)

CAPS Rating: 1 out of 5 19.09

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

42 Outperform
17 Underperform
 

All-Star Players

6 Outperform
9 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top ADXS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

GorGecko99 (24.96)
Submitted May 22, 2016

Leader in immunotherapy research. Great long-term potential.

zzlangerhans (99.78)
Submitted October 09, 2015

Advaxis has pulled off the surprising feat of not only recovering all the ground lost on the after hours plunge on Tuesday after announcement of the ADXS-HPV clinical hold, but they've actually gained ground from before the hold was announced. And… More

ADXS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ADXS.

Recs

0
Member Avatar Bigsef77 (68.30) Submitted: 3/13/2018 10:04:36 AM : Underperform Start Price: $23.99 ADXS Score: +129.98

Advaxis Inc. ADXS, -14.93% shares sank in the extended session Monday after the biotech company's cancer-drug study was placed on hold following the death of a patient in the study. Advaxis shares fell 24% after hours, following an initial halting. Shares finished up 0.5% at $2.21 in regular trading Monday. The clinical hold affects the company's clinical trial for the combination of the drugs Imfinzi and axalimogene filolisbac for the treatment of human papillomavirus-associated cervical cancer and HPV-associated head and neck cancer. "Enrollment and further dosing are on hold in this trial while the company, its partner and the [Food and Drug Administration] work closely with the site investigator to review this event in detail and to resolve this clinical hold," the company said in a statement.

Recs

0
Member Avatar Sparticus501 (< 20) Submitted: 5/25/2016 8:45:23 PM : Outperform Start Price: $8.74 ADXS Score: -128.60

Leader in cancer immunotherapy. Many different potential successful drugs in the FDA pipeline.

Recs

1
Member Avatar GorGecko99 (24.96) Submitted: 5/22/2016 11:58:23 AM : Outperform Start Price: $7.92 ADXS Score: -130.71

Leader in immunotherapy research. Great long-term potential.

Leaderboard

Find the members with the highest scoring picks in ADXS.

Score Leader

TheSlightEdge

TheSlightEdge (98.78) Score: +375.10

The Score Leader is the player with the highest score across all their picks in ADXS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
NobleOrSomeBull 99.49 2/9/2016 Underperform 5Y $5.48 -93.36% +50.23% +143.59 0 Comment
patatepoil6 99.89 3/4/2016 Underperform 5Y $8.82 -95.87% +38.57% +134.44 0 Comment
ziggystraw 99.06 1/9/2015 Underperform 5Y $10.14 -96.41% +35.97% +132.38 0 Comment
km00nster < 20 6/9/2015 Underperform 5Y $26.75 -98.64% +33.39% +132.03 0 Comment
vaipalolo 84.57 6/15/2015 Underperform 1Y $23.00 -98.42% +33.27% +131.69 0 Comment
Zencyclone 30.48 3/16/2015 Underperform 5Y $14.05 -97.41% +33.85% +131.26 0 Comment
Iwannabeadored 39.51 4/20/2015 Underperform 5Y $18.65 -98.05% +33.00% +131.05 0 Comment
Clint35 62.95 5/1/2015 Underperform NS $17.12 -97.87% +32.79% +130.66 0 Comment
Bigsef77 68.30 4/24/2015 12/14/2018 Underperform 3Y $23.99 -98.48% +31.50% +129.98 1 Comment
SimonSaysSell 97.58 12/29/2014 Underperform NS $8.97 -95.94% +33.20% +129.14 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ADXS.

Advertisement